The observed upregulation of PD-1 and PD-L1, along with increased TIGIT and CD112/CD155 expression in severe cases, suggests that these markers may serve as potential biomarkers for identifying high-risk COVID-19 patients with worse prognosis and the need for more intensive clinical monitoring. Here, TIGIT is linked to COVID-19.